…
dorsaVi Ltd develops and sells motion analysis technologies in Australia, Europe, and the United States. It operates through three segments: Clinical, Workplace, and RRAM. The company provides ViMove+, a clinical and sports solutions; VideoAI, a visual movement data; ViSafe+, a measure movement, identify risk, and support proactive safety programs; and Research+, a precision tools for movement research. It serves clinic and sports, workplace, and research industries. dorsaVi Ltd was incorporated in 2008 and is based in Oakleigh South, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Dorsavi Ltd develops wearable sensor systems and cloud analytics that quantify human movement and muscle activity for clinical, sports and workplace health applications. Long-term growth may be supported by rising demand for remote monitoring, workplace injury prevention and recurring software subscriptions as adoption broadens across healthcare providers and employers. The company appears positioned to benefit from growing interest in objective mobility metrics and data-driven injury-reduction programs.
Key investment risks include competitive pressure and technology commoditisation, slower-than-expected adoption or reimbursement, execution and international expansion challenges, and potential need for additional capital to fund growth.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -8.97M | -1.87M | -1.70M | -2.31M | -2.10M |
| Net income | -8.52M | -1.52M | -1.25M | -1.82M | -1.54M |
| Selling general administrative | - | 0.97M | 1.43M | 2.12M | 3.08M |
| Selling and marketing expenses | - | 0.07M | 0.06M | 0.18M | 0.20M |
| Gross profit | -3.33M | 0.97M | 1.18M | 1.58M | 2.52M |
| Reconciled depreciation | - | - | 0.08M | 0.18M | 0.18M |
| Ebit | -7.48M | -1.88M | -1.68M | -2.07M | -1.71M |
| Ebitda | -7.36M | -1.82M | -1.60M | -1.88M | -1.53M |
| Depreciation and amortization | 0.12M | 0.06M | 0.08M | 0.18M | 0.18M |
| Operating income | -7.48M | -1.88M | -1.69M | -2.30M | -2.68M |
| Other operating expenses | 8.48M | 3.63M | 3.00M | 3.33M | 3.51M |
| Interest expense | 0.01M | 0.01M | 0.02M | 0.24M | 0.39M |
| Tax provision | - | -0.36M | -0.46M | -0.49M | -0.56M |
| Interest income | - | 0.01M | 0.01M | 0.24M | 0.39M |
| Net interest income | - | - | -0.01M | -0.24M | -0.39M |
| Income tax expense | -0.45M | 0.36M | -0.46M | -0.49M | -0.56M |
| Total revenue | 1.00M | 1.13M | 1.30M | 1.83M | 2.80M |
| Total operating expenses | 4.15M | 3.47M | 3.64M | 3.87M | 4.90M |
| Cost of revenue | 4.33M | 0.16M | 0.12M | 0.25M | 0.28M |
| Total other income expense net | -1.49M | 0.01M | -0.01M | 0.22M | 0.67M |
| Net income from continuing ops | - | - | -1.25M | -1.82M | -1.54M |
| Net income applicable to common shares | - | -1.52M | -1.25M | -1.82M | -1.54M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 5.85M | 3.97M | 2.18M | 2.69M | 3.36M |
| Intangible assets | 1.49M | 0.32M | - | - | - |
| Other current assets | 1.07M | 0.52M | 0.13M | 0.18M | 0.72M |
| Total liab | 1.51M | 1.14M | 1.16M | 1.01M | 2.13M |
| Total stockholder equity | 4.34M | 2.84M | 1.02M | 1.68M | 1.22M |
| Other current liab | 0.61M | 0.71M | 0.45M | 0.37M | 1.48M |
| Common stock | 58.91M | 50.58M | 47.29M | 46.33M | 44.53M |
| Capital stock | - | - | - | 46.33M | 44.53M |
| Retained earnings | -56.17M | -47.84M | -46.53M | -45.28M | -43.71M |
| Other liab | - | - | - | 0.01M | 0.00M |
| Other assets | - | - | 0.00M | - | 0.00M |
| Cash | 2.12M | 2.29M | 0.48M | 0.88M | 0.45M |
| Cash and equivalents | - | - | - | - | 0.45M |
| Total current liabilities | 1.49M | 1.06M | 1.05M | 0.98M | 2.07M |
| Current deferred revenue | 0.27M | - | 0.38M | 0.27M | 0.38M |
| Net debt | -2.06M | -2.14M | -0.29M | -0.56M | -0.26M |
| Short term debt | 0.05M | 0.09M | 0.09M | 0.30M | 0.13M |
| Short long term debt | - | - | - | 0.26M | 1.08M |
| Short long term debt total | 0.07M | 0.16M | 0.19M | 0.32M | 0.19M |
| Other stockholder equity | - | - | - | -1.04M | -0.83M |
| Property plant equipment | - | - | - | 0.16M | 0.29M |
| Total current assets | 4.26M | 3.51M | 1.96M | 2.53M | 3.07M |
| Net tangible assets | - | - | - | 1.68M | 1.22M |
| Net receivables | 0.71M | 0.26M | 0.86M | 0.95M | 0.49M |
| Long term debt | - | - | - | - | 0.00M |
| Inventory | 0.36M | 0.43M | 0.49M | 0.53M | 0.52M |
| Accounts payable | 0.55M | 0.27M | 0.13M | 0.04M | 0.08M |
| Accumulated other comprehensive income | 1.60M | 0.09M | 0.27M | 0.64M | 0.40M |
| Non currrent assets other | - | - | 0.02M | -0.16M | -0.29M |
| Non current assets total | 1.59M | 0.47M | 0.22M | 0.16M | 0.29M |
| Capital lease obligations | - | - | - | 0.06M | 0.10M |
| Long term debt total | - | - | - | - | 0.06M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | - | -0.02M | -0.05M | -0.10M |
| Change to liabilities | - | - | - | -0.02M | -0.46M |
| Total cashflows from investing activities | -0.01M | -0.30M | -0.02M | -0.05M | -0.10M |
| Net borrowings | - | - | -0.20M | 0.12M | -0.09M |
| Total cash from financing activities | 5.12M | 3.08M | 0.23M | 1.45M | -0.09M |
| Change to operating activities | - | - | - | 0.14M | -0.20M |
| Net income | -8.52M | -1.52M | -1.25M | -1.82M | -1.54M |
| Change in cash | -0.17M | 1.82M | -0.40M | 0.43M | -2.35M |
| Begin period cash flow | 2.29M | 0.48M | 0.88M | 0.45M | 2.80M |
| End period cash flow | 2.12M | 2.29M | 0.48M | 0.88M | 0.45M |
| Total cash from operating activities | -5.28M | -0.96M | -0.60M | -0.97M | -2.15M |
| Issuance of capital stock | - | - | 0.50M | 1.45M | - |
| Depreciation | 0.12M | 0.06M | 0.08M | 0.18M | 0.18M |
| Other cashflows from investing activities | - | -0.30M | -0.02M | - | - |
| Dividends paid | - | - | - | 0.30M | 1.33M |
| Change to inventory | 0.07M | - | 0.04M | -0.00M | 0.10M |
| Change to account receivables | -0.05M | - | 0.08M | 0.21M | 0.21M |
| Sale purchase of stock | - | 3.38M | -0.03M | -0.12M | -0.12M |
| Other cashflows from financing activities | -0.04M | -0.26M | -0.04M | 0.56M | 0.01M |
| Change to netincome | - | - | - | 0.34M | -0.46M |
| Capital expenditures | 0.00M | 0.00M | 0.02M | 0.05M | 0.10M |
| Change in working capital | -0.71M | 0.02M | 0.41M | 0.20M | 0.32M |
| Stock based compensation | - | 0.00M | - | 0.43M | 0.27M |
| Other non cash items | 3.84M | 0.50M | 0.15M | 0.67M | -0.80M |
| Free cash flow | -5.28M | -0.96M | -0.62M | -1.02M | -2.25M |
Sector: Technology Industry: Scientific & Technical Instruments
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| DVL Dorsavi Ltd |
0.00 5.26% |
0.02 | - | 3.27 | 27.31 | 6.32 | 25.27 | -5.11 |
| CDA Codan Ltd |
-1.83 3.16% |
56.07 | 58.46 | 36.76 | 11.69 | 17.92 | 12.47 | 38.25 |
| CAT Catapult Group International Ltd |
-0.05 1.31% |
3.76 | - | 49.02 | 8.40 | 3.56 | 5.03 | 46.83 |
| OIL Optiscan Imaging Ltd |
0.00 1.29% |
0.16 | - | 10.82 | 44.85 | 8.28 | 320.51 | -12.11 |
| IKE Ikegps Group Ltd |
- -% |
0.70 | - | - | 4.96 | 6.72 | 5.61 | -3.62 |
dorsaVi Ltd develops and sells motion analysis technologies in Australia, Europe, and the United States. It operates through three segments: Clinical, Workplace, and RRAM. The company provides ViMove+, a clinical and sports solutions; VideoAI, a visual movement data; ViSafe+, a measure movement, identify risk, and support proactive safety programs; and Research+, a precision tools for movement research. It serves clinic and sports, workplace, and research industries. dorsaVi Ltd was incorporated in 2008 and is based in Oakleigh South, Australia.
11-13 Milgate Street, Oakleigh South, VIC, Australia, 3167
61 3 1800 367 728
| Name | Title | Year Born |
|---|---|---|
| Dr. Andrew James Ronchi B.App.Sci., GAICD, Ph.D. | Co-Founder, MD, CEO & Exec. Director | NA |
| Mr. Troy Di Domenico | Chief Financial Officer | NA |
| Mr. Daniel Mathew Ronchi Ass.Deg.Law | Chief Technology Officer | NA |
| Ms. Joanna Goldin | Clinical Mang. | NA |
| Mr. Brendan T. Case BEc, C.P.A., CPA, Dip FP, FCIS, Grad Dip., MComLaw | Company Sec. | NA |
| Dr. Andrew James Ronchi B.App.Sci., GAICD, Ph.D. | Co-Founder, MD, CEO & Executive Director | NA |
| Mr. Aaron Chan | Chief Financial Officer | NA |
| Mr. Justin Mouchacca B.Bus (Acc), C.A., CA | Company Secretary | NA |
| Dr. Andrew James Ronchi B.App.Sci., GAICD, Ph.D. | Co-Founder, MD, CEO & Executive Director | NA |
| Mr. Aaron Chan | Chief Financial Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.